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Background: microRNAs have recently succeeded in grabbing the center stage in cancer research for their
potential to regulate vital cellular process like cell cycle, stem cell renewal and epithelial mesenchymal transition.
Breast cancer is the second most leading cause of cancer related mortality in women. The main reason for mortality
is chemoresistance and metastasis for which remnant stem cells are believed to be the cause. One of the natural
ways to reduce the risk of breast cancer in women is early pregnancy. Unraveling the mechanism behind it would
add to our knowledge and help in evolving newer paradigms for breast cancer prevention.
The current study deals with investigating transcriptomic differences in putative stem cells in mammary epithelial
cell population (MECs) in terms of genes and microRNAs. In silico tools were used to identify potential mechanisms.
ALDH positive MECs represent a putative stem cell population in the mammary gland.
Methods: MECs were extracted from the mammary gland of virgin and parous (one time pregnant) rats. ALDH
positive MECs were sorted and used for transcriptional and translational analysis for genes and microRNAs. In silico
analysis for target prediction and networking was performed through online portals of Target Scan and Metacore.
Results: A total of 35 and 49 genes and microRNAs respectively were found to be differentially expressed within
the two groups. Among the important genes were Lifr, Acvr1c, and Pparγ which were found to be targeted by
microRNAs in our dataset like miR-143, miR-30, miR-140, miR-27b, miR-125a, miR-128ab, miR-342, miR-26ab, miR-181,
miR-150, miR-23ab and miR-425. In silico data mining and networking also demonstrates that genes and
microRNA interaction can have profound effects on stem cell renewal, cell cycle dynamics and EMT processes
of the MEC population.
Conclusions: Our data clearly shows that certain microRNAs play crucial role in the regulation of ALDH positive
MECs and favor an anti-carcinogenic environment in the post-partum gland. Some of the potential interplaying
mechanisms in the ALDH positive MEC population identified through this study are p21, Lifr and Pparγ mediated
cell cycle regulation, regulation of metastasis and expansion of stem cell pool respectively.
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Breast cancer is one of the primary causes of cancer-related
deaths and the most common malignancy in women
worldwide [1]. Despite different existing and potential strat-
egies to treat breast cancer, its global incidence is predicted
to increase in the coming years at a rate of 3.2 million new
cases every year by 2050 [2]. Currently, while there are
good treatment options for patients with breast cancer, a
high percentage of patients develop resistance to these
treatments over time, and these therapies often have
undesirable and harmful side effects.
It is well known that early, full-term pregnancy
reduces the risk of breast cancer. A completed full-term
pregnancy before the age of 20 years reduces breast
cancer risk by 50% compared to nulliparous women [3].
While this fact has been known for a long time, different
reasons have been brought forward repeatedly to explain
this phenomenon. Unfortunately, the mechanism behind
this protective phenomenon is not well defined. One pos-
sible explanation is that parous women often have a differ-
ent hormonal profile compared to nulliparous women [4].
Thus, it is thought that alterations in the hormonal milieu
both during and after pregnancy may contribute to the
phenomenon of parity-induced protection against breast
cancer. Animal studies have proven that short-term treat-
ment with pregnancy levels of estrogen can be effective in
reducing mammary cancer incidence [5,6]. Also of special
interest is the hormone prolactin, which has been found
at reduced levels in the sera of parous women; coinciden-
tally, prolactin-suppressing drugs have been shown to re-
duce mammary tumors [7]. Further, growth hormone has
also been demonstrated to be vital for breast cancer devel-
opment and parity reduces the levels of growth hormone
in circulation [8-10]. Thus, strong evidence suggests a
definitive role for hormones in parity-induced protection
against breast cancer. Further, some researchers have sug-
gested that pregnancy results in the terminal differenti-
ation of the mammary gland, resulting in the loss of a
particular cell population that is prone to malignant trans-
formation [11,12]. However, other studies indicate that
differentiation of the mammary gland per se is not
sufficient to explain the phenomenon of parity-induced
protection against breast cancer [5,6,13].
It has been well established that the mammary gland is
partly comprised of a population of epithelial stem cells
that are capable of self-renewal and are responsible for the
generation of newer cell types specific to the gland. There-
fore, a third theory was proposed that breast cancer arises
primarily from the stem cell compartment and pregnancy
may lead to protective changes in the stem cell population
of the mammary gland. However, it remains highly debat-
able whether the mammary epithelial stem cell population
is a primary contributing factor to the phenomenon of
parity-induced protection [14-17], and additional work inthis area is therefore needed. A recent report by Siwko
et al. [14] suggested that there is a persistent decrease in
the number of mammary-repopulating units (mammary
epithelial stem cells) after parity. In contrast, there are
reports, including ours, which demonstrate that parity-
induced protection is not due to changes in the number of
cells in the mammary epithelium itself but is the result of
systemic changes in the whole organism [18-20]. Thus, it
is imperative to understand how the systemic environ-
ment influences mammary epithelial stem cells and how
this may contribute to the protective phenomenon of
parity. The significance of this study lies in the notion that
stem cells are the initiators of carcinogenesis, according to
the cancer stem cell theory.
Over the last couple of years, research in the field of
breast cancer, has added strong lines of evidence, support-
ing the fact that microRNAs have a significant role to play
in the regulation of the signaling pathways involved in
oncogenesis. They have also been implicated in the
maintenance of cancer stem cells via their ability to affect
multiple pathways including cell proliferation, cell death
[21-23], cell- cell communication and cell adhesion [24].
In this study, we demonstrate that pregnancy alters mo-
lecular processes in ALDH positive MECs (putative mam-
mary epithelial stem cells), leading to a decreased risk of
mammary cancer. Here, we primarily focused on the gen-
etic differences of ALDH positive MECs from both virgin
and parous animals, through gene and microRNA profil-
ing. To the best of our knowledge, this is the first study to
identify the parity-induced microRNA signature in the
ALDH positive MECs that is associated with the reduced
risk of breast cancer.
Methods
Animals
Virgin Lewis rats were purchased from Harlan Sprague–
Dawley (Indianapolis and San Diego). The rats were
housed in temperature controlled room with 12-h light/
dark schedule. They were fed (Teklad 8640; Teklad,
Madison, WI) and water ad libitum. To generate parous
animals, seven week old virgin rats were mated with
similar aged male rats. The pups were removed from
the cage right after parturition. The mammary glands
from the parous rats were removed six weeks after partur-
ition to allow involution of the gland. Mammary glands
were removed from age-matched virgin rats and used as
controls. All procedures performed were approved and
conducted in accordance with the Texas Tech University
Health Sciences Center Institutional Animal Care and Use
Committee’s guidelines.
Mammary epithelial cell isolation and stem cell enrichment
Isolation of MECs from the mammary gland was carried
out using collagenase assisted cell dissociation. Briefly,
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uniparous (one-time pregnant) Lewis rats were processed
by mechanical and enzymatic dissociation to prepare a
single-cell suspension. MECs were cultured overnight.
They were then stained with ALDEFLUOR (Stem Cell
Technologies), which enabled the selection of putative
stem cells from MECs with strong aldehyde dehydro-
genase (ALDH) activity. An inhibitor of ALDH was used
as the negative control. The cells were analyzed on a
flow cytometer in the green fluorescence channel (520–
540 nm) and were then subjected to sorting. Sorting
was performed using a flow cytometric cell sorter (BD
FACS Aria) to collect the ALDHbright population. These
sorted ALDH positive MECs were then used to prepare
RNA and protein lysates for transcriptional and transla-
tional analysis, respectively.Mammosphere assay
The mammosphere formation assay was performed as
previously described [25]. Briefly, MECs from both vir-
gin and parous animals were plated after preparation of
a single-cell suspension using a 23-G needle. Cells were
plated in ultralow attachment 6-well plates (Corning)
with mammosphere media containing B27 supplement
and LONZA Single Quot supplements (hydrocortisone,
insulin, beta-mercaptoethanol, EGF, and gentamycin) in
phenol red-free DMEM/F12 media (GIBCO). The cell
density of this assay was optimized to 500 cells/cm2.
The cells were not disturbed for 5 days before any change
in media. After 7 days, any sphere larger than 50 μm was
considered for counting and further analysis, using a
sample size of six.Immunofluorescence
The mammospheres were collected by centrifugation at
115 × g for 5 min and were gently suspended in 200 μl
mammosphere media. They were then plated on poly-
lysine coated; 8-well chambered slides with mammo-
sphere assay containing 1% fetal bovine serum and incu-
bated at 37°C, with 5% CO2 for 3–4 hrs for attachment.
These mammospheres were then fixed using 5% formal-
dehyde and blocked with 5% bovine serum albumin for
1 hr. They were then stained for stem cell markers using
primary antibodies against SOX2 (goat IgG clone Y-17,
1:100 dilutions, Santa Cruz Biotechnology) and OCT3/4
(mouse IgG2b clone C-10, 1:50 dilution, Santa Cruz Bio-
technology). Alexafluor 488 and 594 were used as sec-
ondary antibodies raised in species appropriate for the
primary antibody. The spheres were washed and coun-
terstained with DAPI and mounted. All slides were ex-
amined using a Nikon confocal microscope (Eclipse Ti,
Nikon, Japan). Multicolor images were collected sequen-
tially in three channels.Proliferation assay
An EdU (5-ethnyl-2′-deoxyuridine) based kit; Click-iT
EdU Imaging kit was used to perform the assay (Mo-
lecular probes, Life technologies). The sorted ALDH
positive MECs were plated in the 8 well chamber slide
with 1 × 104 cells/ well and incubated overnight at 37°C/
5% CO2. 10 μM of EdU was incubated with the cells for
2 hrs at 37°C/5% CO2. The cells were then fixed with
3.7% formaldehyde for 15 min and permeabilized with
0.5% Triton-X-100 for 20 min. It was then incubated
with Alexa fluor azide for 30 min to enable the detec-
tion of EdU. They were finally counterstained with
DAPI and mounted for examination using a Nikon
confocal microscope (Eclipse Ti, Nikon, Japan).
Gene and microRNA arrays and in silico analysis
Gene and global microRNA profiles were generated using
the SABiosciences PCR (Cat No. PARN-405Z and PARN-
047Z) and miRNome array (Cat No. MIRN-216Z), re-
spectively. Briefly, RNA was extracted from ALDHpositive
MECs of both virgin and parous animals using Trizol
(Invitrogen). Replicates of mammary tissues from at least
six animals from each group were used for gene and
miRNome array analyses. For the gene array, 160 genes
associated with stemness and stem cell development
were analyzed. For the microRNA array, 653 of the most
abundantly expressed and well-characterized microRNAs
in the rat microRNA genome as annotated by miRBase
Release 16 were profiled. Genes or microRNAs with at
least a 2-fold increase or decrease in expression were con-
sidered significantly up- or downregulated, respectively.
For microRNA target prediction, the main in silico
approach used depends on sequence complementarity.
To predict the targets for the microRNA array, we used
the online portal of TargetScan. The targets in which the
paired sites were highly conserved were considered for
further analysis. TargetScan (http://www.targetscan.org/)
predicts the biological targets of microRNAs by searching
for the presence of conserved 8mer and 7mer sites that
match the seed region of each microRNA. To increase the
signal-to-noise ratio, TargetScan requires strict comple-
mentarity between the seed region of the microRNA and
the predicted target. TargetScan Human considers matches
to annotate human UTRs and their orthologs, as defined
by UCSC whole-genome alignments (http://genome.
ucsc.edu/). Conserved targeting has also been detected
within open reading frames (ORFs). MetaCore from
Thomson Reuters was used to perform data mining and
pathway analysis for the differentially regulated micro-
RNAs and genes.
Western blot analysis
Protein lysates of ALDH positive MECs were prepared
from glands of virgin and parous animals. Protein
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(bicinchoninic acid) protein assay (Thermo Scientific) ac-
cording to the manufacturer’s specifications. Equivalent
amounts of protein (1 – 5 μg) were resolved using reducing
SDS-PAGE in 4-20% gradient pre-cast Mini-Protean TGX
polyacrylamide gels (Bio-Rad). Resolved proteins were
transferred onto PVDF immunoblotting membranes and
probed with the following antibodies as per manufacturer’sFigure 1 Quantitative and qualitative analysis of ALDH positive MECs
was established from virgin and parous MECs after cell dissociation of the
rat MECs after 7 days in culture B) Percentage of ALDHbright virgin and paro
detected using the green fluorescence channel (520–540 nm) of the flow c
mammospheres formed after 7 days in culture were counted and divided
images showing the presence of stem cell markers like SOX2 and OCT4 in
Mammospheres, after 7 days in culture were placed on poly-l-lysine coated
double immunofluorescence staining procedure. The cells from both group
stem cells in the mammospheres.instructions: LIFR, PPAR γ, CYCLIN D, ACVR1C, LIN 28
(Santa Cruz), NOTCH 2, CYCLIN E1, SNAIL, SLUG,
VIMENTIN, N-CADHERIN, E-CADHERIN, ZEB (Cell
Signaling) and P21 (Abcam). Each membrane was also
stripped and reprobed for β-actin as protein loading. For
chemiluminescent detection of proteins, SuperSignal West
Femto Chemiluminescent Substrate (ThermoScientific)
was used according to the manufacturer’s instructions.in virgin and parous glands. Mammosphere formation assay (n = 6)
mammary gland. A) Mammospheres obtained from virgin and parous
us MECs using flow cytometry. The positively stained cells were
ytometer. C) Mammosphere formation efficiency; total number of
by the total number cells initially plated. D) Immunofluorescence
mammospheres obtained from MECs of both the groups.
chamber slides for attachment for 3-4 hrs and followed by sequential
s showed positivity for SOX2 and OCT4 indicating the enrichment of
Figure 2 Pregnancy alters gene expression profile in ALDH positive MECs. Putative stem cells were obtained from both virgin and parous
glands by sorting for ALDHbright population. RNA was extracted and cDNA was prepared post DNAase treatment. PCR array was performed (n = 6)
to evaluate the expression status of stem cell associated genes in these cells from the two groups. A threshold of 2 folds up- or down-regulation
was considered to generate a dataset of the differentially regulated genes between the two groups. A) Relative expression of all up regulated
genes in ALDH positive MECs of parous rats compared to virgin B) Relative expression of all down regulated genes in ALDH positive MECs of
parous animals compared to virgin C) & D) Volcano plot of gene expression between parous and virgin ALDH positive MECs, demonstrating the
most significantly differentially expressed genes in two different arrays.
Table 1 List of genes up regulated in ALDH positive MECs
derived from normal parous as compared to virgin
mammary gland of rat
mRNA Description GeneBank ID p- value
(t-test)
Acvr1c Activin A receptor, type IC NM_139090 0.000045
Lifr Leukemia inhibitory factor
receptor alpha
NM_031048 0.0084
Rgma RGM domain family, member A NM_001107524 0.0016
Smad9 SMAD family member 9 NM_138872 0.03
Fgf3 Fibroblast growth factor 3 NM_130817 0.123




Neurog2 Neurogenin 2 XM_227716 0.101
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Quant LAS4000 biomolecular imager (GE Healthcare).
The signal intensities for each antibody was densitomet-
rically analyzed and normalized to actin bands.
Statistical analysis
Data are expressed as means with standard deviation or
standard error. Student’s t-test was used to determine stat-
istical significance between 2 groups. A value of p < 0.05
was considered a statistically significant difference.
Results
The main aim of this study was to determine the molecu-
lar differences in ALDH positive MECs as a result of preg-
nancy. The model system that we used for this study is
FACS-enriched MECs positive for ALDH from virgin and
parous animals.
Parity does not influence the proportion or stemness of
ALDH positive MECs
First, we quantified ALDH positive MECs from virgin and
parous animals; we did not observe a statistically significant
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the two groups (p = 0.22) (Figure 1A & 1B). Additionally,
there were no statistically significant differences in their
mammosphere-forming capacities (p = 0.35) (Figure 1C).
The presence of stem cells in mammospheres derived from
virgin and parous MECs was confirmed using stemness
markers SOX2 and OCT4 (Figure 1D). Overall, the data
indicate that parity does not influence the stem cell popu-
lation by significantly altering the percentage of ALDH
positive MECs compared to a virgin mammary gland. On
contrary, our cell proliferation experiment indicated
that virgin ALDH positive MECs had a slightly higherFigure 3 Regulation of target protein expression by differentially expre
animals. Proteins were extracted from ALDH positive MECs of virgin and paro
for every protein. A) & B) Immunoblots and corresponding densitometry grap
ACVR1C, LIFR, CYCLIN E,NOTCH 2, LIN 28, P21 and PPARγ C) Immunoblots and
N-Cadherin, SLUG, Vimentin and E-Cadherin demonstrate enhanced EMT liproliferation rate than parous ALDH positive MECs
(Additional file 1: Figure S1).
Parity induces alterations in the genetic environment of
the ALDH positive MEC population
We next investigated potential differences in the expres-
sion of genes that influence stemness and stem cell proper-
ties of ALDH positive MECs in virgin and parous animals.
We identified a total of 21% (35/168) of genes that were
differentially expressed in parous compared to virgin
ALDH positive MECs. We observed that leukemia inhibi-
tory factor receptor (Lifr), RGM domain family member Assed microRNAs in the ALDH positive MECs of parous and virgin
us rat mammary gland. The western blots were repeated atleast thrice
hs of proteins (n = 6) for some of the differentially regulated genes e.g.
densitometric analysis for EMT related markers like ZEB, SNAIL,
ke characteristics at the translational level in virgin ALDH positive MECs.
Table 2 List of genes down regulated in mammary
epithelial SC derived from normal parous as compared to
virgin mammary gland of rat
mRNA Description GeneBank ID p-value
(t-test)
Acvrl1 Activin A receptor type II-like 1 NM_022441 0.0043
Bcl9 B-cell CLL/lymphoma 9 NM_001107703 0.122
E2f5 E2F transcription factor 5 XM_574892 0.0003
Eng Endoglin NM_001010968 0.0001
Fzd1 Frizzled homolog 1 (Drosophila) NM_021266 0.02
Fzd6 Frizzled homolog 6 (Drosophila) NM_001130536 0.0001
Fzd7 Frizzled homolog 7 (Drosophila) XM_237191 0.46
Notch3 Notch homolog 3 (Drosophila) NM_020087 0.0003
Ptchd2 Patched domain containing 2 NM_001107992 0.667
Rbl1 Retinoblastoma-like 1 (p107) XM_001055763 0.01
Tcf7l2 Transcription factor 7-like 2
(T-cell specific, HMG-box)
XM_001054844 0.001
Zeb2 Zinc finger E-box binding
homeobox 2
NM_001033701 0.016
Abcg2 ATP-binding cassette, subfamily
G (WHITE), member 2
NM_181381 0.224
Acan Aggrecan NM_022190 0.292






Bmp2 Bone morphogenetic protein 2 NM_017178 0.849
Ccne1 Cyclin E1 NM_001100821 0.892
Cd4 CD4 molecule NM_012705 0.285
Cdk1 Cyclin-dependent kinase 1 NM_019296 0.043
Fgf1 Fibroblast growth factor 1 NM_012846 0.333
Foxa2 Forkhead box A2 NM_012743 0.231
Igf1 Insulin-like growth factor 1 NM_178866 0.014
Myst1 MYST histone acetyltransferase 1 NM_001017378 0.023
Tert Telomerase reverse transcriptase NM_053423 0.021
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receptor, type IC (Acvr1c) were all strongly upregulated
in parous ALDH positive MECs (Figure 2; Table 1). Fur-
ther, Lifr was the most upregulated gene, exhibiting a
7.6-fold increase in parous compared to virgin ALDH
positive MECs. We investigated the protein levels of
some of these differentially regulated genes, including LIFR,
NOTCH2, ACVR1C, p21, CYCLIN D, CYCLIN E1, LIN
28, PPAR γ, SNAIL, SLUG, VIMENTIN, N-CADHERIN,
E-CADHERIN and ZEB2. Interestingly, we found the same
trend was reflected at the protein level as well (Figure 3).
The downregulated genes in parous ALDH positive MECs
included the metastasis-promoting gene, Zeb2, cell
cycle-associated E2F transcription factor 5 (E2f5) cyclin
E1 (Ccne1) and retinoblastoma-like protein 1 (Rbl1) in-
dicating inhibitory activity at the G1–S phase of the cell
cycle (Figure 2; Table 2).
Several of the differentially regulated genes were found
to be involved in cell cycle regulation, stem cell self re-
newal, and differentiation, including Ccne1, Fgf1, Fgf3,
Notch2, Myst histone acetyltransferase 1 (Myst1), Neu-
rogenin 2 (Neurog2), Forkhead box A2 (Foxa2), and ISL
Lim homeobox 1 (Isl1). In addition, our stem cell gene
array data indicates that TGF-β, NOTCH, and WNT
pathways which are involved in stem cell regulation
were most influenced by parity. Interestingly, genes as-
sociated with identification of stemness, such as Abcg2
and Aldh1a1, were down regulated in parous ALDH
positive MECs.
MicroRNA profiles in virgin and parous ALDH positive
MECs
With the aim of finding novel mechanisms for parity-
induced protection against breast cancer, we next inves-
tigated global microRNA expression in parous and virgin
ALDH positive MECs. The global microRNA profiling
data revealed differential regulation of 7.5% (49/653) of
the total microRNAs between virigin and parous ALDH
positive MECs. Among the differentially regulated micro-
RNAs 12.2% (6/49) and 87.8% (43/49), were up and down
regulated respectively; in parous compared to virgin ALDH
positive MECs (Figure 4, Table 3 & 4). This screening con-
firmed the differential expression of several microRNAs in
parous ALDH positive MECs that have been reported to
be associated with breast and other cancers (Table 5).
Many of the downregulated microRNAs in parous
ALDH +MECs have been previously reported to be
pro-carcinogenic (Table 5). In contrast, a few of the up-
regulated microRNAs in this case have been previously
reported as anti-carcinogenic in nature (Table 5).
miR-497, miR-218a, miR-378*, miR-503, miR-7a/7c and
miR-221 were upregulated in parous ALDH positive MECs.
Most of these microRNAs have been shown to have tumor
suppressive properties in breast and other cancers. miR-497, miR-218a, miR-378 and miR-503 were reported to
have anti-carcinogenic effect in breast, glioma, liver, endo-
metrial and gastric cancers respectively. These microRNAs
suppress tumor growth by affecting cell proliferation, stem
cell renewal, angiogenesis and cancer cell metabolism
[26-31]. miR-221 has been shown to be involved in the
promotion of epithelial-mesenchymal transition (EMT)
in breast cancer cell lines, where it is regulated by Slug
[32]. However, in normal human umbilical vein endo-
thelial cells, miR-221 has been shown to directly target
and repress Zeb2 [33].
Both miR-27b and miR-181b were among the most
downregulated microRNAs in parous compared to nul-
liparous ALDH positive MECs. Positive expressions of
both these microRNAs have been correlated with poor
Figure 4 Whole genome microRNA array revealed the differentially regulated microRNAs among virgin and parous ALDH positive
MECs. Primary rat MECs were obtained after cell dissociation of the mammary gland tissue from virgin and parous animals. The primary cells
were subjected to ALDH staining followed by flow cytometric sorting of ALDHbright cell population. RNA was extracted and cDNA (small
microRNA specific) was prepared from these cells. The cDNA was then used to perform whole genome microRNA profiling (n = 6) for ALDH
positive MECs from both the groups. MicroRNAs that were 2 folds up-or-down-regulated between the groups were considered as differentially
regulated. A) microRNAs in ALDH positive MECsof parous compared to the virgin glands with a fold down regulation of 0.01 and 0.1. B) Sub
graph showing the microRNAs which had a fold down regulation between 0.1 and 0.5. This group had the most number of down regulated
microRNAs from the dataset. C) Up regulated microRNAs in ALDH positive MECs of the parous compared to the virgin glands which had a fold
up regulation > 2 through 15. D) Sub group of microRNAs which had a fold up regulation of >15.
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tumor suppression and neoplastic transformation (high
mobility group A proteins) [34,35].
Thus, the microRNA prolife of parous ALDH positive
MECs appears to favor anti-carcinogenesis, at least con-
sidering the differentially expressed microRNAs observed
in this study. However, functional studies to further
support this statement are warranted.
In silico analysis reveals interconnections between
differentially regulated microRNAs and genes
The results of the in silico analysis utilizing TargetScan
revealed that many of the differentially regulated genes
in our gene array can possibly be regulated by some of
the differentially regulated microRNAs from the global
microRNA profile (Table 3 & 4). Among the most tar-
geted genes was Lifr, which drew our attention. It was
found to be targeted by multiple microRNAs in our
analysis, including miR-143, miR-30 family members,miR-140, miR-27b, miR-125a-5p, miR-128ab, and miR-
342-3p. Interestingly, all these microRNAs were downreg-
ulated in the miRnome analysis, and correspondingly, Lifr
was upregulated at the transcription and translational
levels in parous ALDH positive MECs (Figure 3). We
also looked at genes other than the ones differentially
expressed in our gene array analysis Figure 5 and found
that miR-125a targets many cell cycle genes, like Ccnd1,
p21, and Cdk2, which may prove to be instrumental in
unraveling the mechanism of parity-induced protection
against breast cancer. Previously, miR-125a-5p was also
reported to target Lin28, which is again very interesting in
the context of stem cells. Here, we have demonstrated that
parous ALDH positive MECs demonstrate a higher ex-
pression of Lin28 at the protein level than nulliparous
ALDH positive MECs (Figure 3B).
Another highly targeted gene in our in silico analysis
was Acvr1c or Alk7, a receptor involved in the nodal-
activin pathway. It was found to be a putative target for
Table 5 Carcinogenic traits of some of the microRNAs
miRNA Carcinogenic trait References
rno-miR-23b Pro-carcinogenic L Jin, 2013 [35]
rno-miR-27b Pro-carcinogenic Wang, 2009 [36]
rno-miR-23a Pro-carcinogenic L Bhushan, 2011 [37]
rno-miR-93 Pro-carcinogenic Liu S, 2009 [38]
rno-miR-103 Pro-carcinogenic Chen HY, 2012 [39]
rno-miR-423 Pro-carcinogenic Farazi TA, 2011 [40]
rno-miR-195 Pro-carcinogenic Heneghan HM, 2010 [41]
rno-miR-196a Pro-carcinogenic Jedlinski DJ, 2011 [42]
rno-miR-342-3p Pro-carcinogenic Savad S, 2012 [43]
rno-miR-135a Pro-carcinogenic Y Chen, 2012 [44]
rno-miR-497 Anti-carcinogenic Shen L, 2012 [45]
Table 3 List of downregulated microRNA in ALDH
positive MECs derived from normal parous as compared
to virgin mammary gland of rat




rno-let-7a, 7d, 7e, 7b, 7c, 7f, 7i ACVR1C, PPARGC1A
rno-miR-26a, 26b ACVR1C
rno-miR-30a, 30e, 30c, 30d LIFR, PPARGC1A, PPARGC1B
rno-miR-181a, 181b ACVR1C, RGMA
rno-miR-140 LIFR
rno-miR-322 RGMA
rno-miR-27b ACVR1C, ISL1, PPARG, LIFR, SMAD9
rno-miR-23ab ACVR1C, Isl1, PPARG






rno-miR-128 ab ACVR1C, ISL1, PPARG, LIFR, SMAD9
rno-miR-342-3p LIFR
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150, miR-27b, miR-23ab, miR-425, miR-125a-5p, and
miR-128ab. However, miR-125a-5p is the only microRNA
that was found to target both Acvr1c and Lifr. Thus, we
believe that Lifr and Acvr1c could be the major players in
the modulation of ALDH positive MECs in response to
pregnancy. Furthermore, because these genes are regu-
lated by miR-125a-5p, it is possible that miR-125a-5p
plays a key regulatory role in putative stem cells of
MECs and is involved in parity-induced protection against
breast cancer.Table 4 List of upregulated microRNA in ALDH positive
MECs derived from normal parous as compared to virgin
mammary gland of rat




rno-miR-503 TCF7L2, BCL9, CCNE1
rno-miR-218a MYST1,IGF1, CCNE1, BCL9, ZEB2Discussion
It is well known that early parity leads to a reduced risk
of breast cancer. In this regard, numerous theories trying
to explain the underlying mechanism have been postulated.
However, at present, it has not been possible to completely
unravel the mechanism behind this phenomenon. Previ-
ously, investigators have studied the differences between
MECs of virgin and parous females of both humans and
rodents. However, in this study, we have directed our ef-
forts to look for the transcriptomic changes in the ALDH
positive MEC population in virgin and parous rats. Our
aim was to determine the underlying mechanism of parity-
induced reduction in breast cancer risk in terms of changes
introduced during the process of pregnancy in the ALDH
positive MEC population. Therefore, in contrast to pre-
vious studies where changes in the entire mammary epi-
thelium were analyzed, our study specifically scrutinized
changes in putative stem cells of the MEC population.
To the best of our knowledge, this is the first report to
describe changes in the global microRNA profiles be-
tween virgin and parous ALDH positive MECs. Our data
identified the gene and microRNA signature induced by
pregnancy in the ALDH positive MECs. Our in vitro
data and in silico analysis led us to speculate about some
of the possible phenomenon that can be attributed to
the parity-induced reduction in breast cancer risk. We
show here that ALDHpositive MECs of parous might
differ from virgin in terms of regulation of the cell cycle,
EMT processes, and tumor suppressors. The mammary
gland is considered as an actively cycling tissue, which
means that putative stem cells are under constant pres-
sure to make decisions on cell cycle progression, prolif-
eration, cell cycle arrest, and differentiation. There are
several genes (Ccne1, Cdk2, E2f5 and Rbl1) in our data-
set that demonstrate the possibility of an alteration in
the regulation of cell cycle of ALDH positive MECs in
response to pregnancy. Down regulation of microRNAs,
like miR-28, miR-125a, and miR-503, could possibly lead
Figure 5 In silico network analysis describing interactions between differentially regulated microRNAs and some of the relevant
proteins. Gene and microRNA datasets were analysed using Metacore from Thomson Reuters to demonstrate existing interactions between
various components of the data sets. A) Descriptive network analyzing the microRNA dataset demonstrating the potential molecular interactions
among microRNAs with many of the genes/proteins associated with stem cell or tumor suppressive/promoting functions. microRNAs in the
dataset were found to be interacting with stem cell associated genes/proteins like BMI-1, LIN-28, SOX2 and NANOG. It was also observed that
many of the microRNAs play a role in the regulation of proto-oncogenes like c-fos and c- and n-Myc or tumor suppressor like FOXO3 and p53.
The interactions were found to be both direct and indirect in nature. B) Network analysis for the microRNAs to visualize their interactions with
proteins involved in cell cycle regulation like P21, RBL1 (p107), PPARγ and CDKs. The interaction and expression levels of microRNAs in the parous
compared to virgin ALDH positive MECs indicates that there possibly can be increased expression of P21 in the stem cells of the former group.
C) Network depicting the possible regulation of EMT related markers like Vimentin, E-Cadherin, Slug, Snail, ZEB1 and HMGA2. Overall, we speculate
that microRNAs like miR-15b and miR-98 co-ordinate the regulation of the expression of E-cadherin, ZEB1 (TCF8), HMGA2 and SNAIL. Similarly,
miR-29a, miR-221 and miR-23b in this network seem to regulate the expression of Vimentin and SLUG indirectly through Caspase 7, AP-1
(activator protein 1) and PAK (p21 protein activated kinase 2).
Nandy et al. BMC Cancer 2014, 14:644 Page 10 of 13
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This increase in p21 levels may lead to cell cycle arrest
in the putative stem cells. This is further supported by
our data, which show a down regulation of other signifi-
cant cell cycle-associated genes, including Ccne1, Cdk2,
E2f5, and Rbl1, in parous ALDH positive MECs. p21 isknown to be suppressed in many human cancers; it was
recently shown in a preclinical study that the up regula-
tion of p21 leads to an anti-proliferative effect in breast
cancer cell lines with cell cycle arrest in G1 phase [46].
Further, our cell proliferation data also indicates a higher
proliferation rate in virgin ALDH positive MECs. These
Nandy et al. BMC Cancer 2014, 14:644 Page 11 of 13
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in virgin mammary glands would have a much greater
chance of accumulating genetic mutations after carcino-
genic insult compared to ALDH positive MECs in parous
mammary gland, which may cycle at a much lower rate.
However, this speculation does not completely explain
the phenomenon of parity-induced reduction in breast
cancer risk. It has been observed in animal models that
upon carcinogenic insult, the frequency of occurrence of
neoplastic lesions is almost similar in both virgin and par-
ous mammary glands [47]. This observation suggests that
lesions in virgin glands are able to progress to breast can-
cer much more rapidly over time than in parous glands.
Therefore, there must be additional factors other than cell
cycle regulators that govern the progression of these neo-
plastic lesions. In this context, it is interesting to note that
Lifr is highly upregulated in parous ALDH positive MECs.
A recent report identified Lifr as a metastasis suppressor
that executes its effects through the Hippo signaling path-
way and prevents EMT [48]. In addition, we demonstrated
the down regulation of Zeb2 and the up regulation of
miR-218a in parous ALDH positive MECs. miR-218a in
this study has been predicted to target Zeb2, which is an-
other factor known to suppress EMT. Interestingly, miR-
218 has been proved to regulate HMGB1 and suppress
migration and invasion. This further supports the idea
that ALDH positive MECs from parous mammary glands
may not undergo EMT as efficiently as those from virgin
glands. If this is indeed the case, then the regulatory envir-
onment of ALDH positive MECs in the parous gland does
not favor progression of the disease. Thus, we speculate
that in response to pregnancy, ALDHpositive MECs are
altered in ways that not only favor slower cell cycle rates,
but also lower efficiency of EMT like events, thus inhibit-
ing progression of the disease. In this regard, our current
data demonstrates that microRNAs likely play a key role
in the regulation of these processes and therefore repre-
sent an important factor to be considered for their contri-
bution to parity-induced reduction in breast cancer risk.
Another important point worth mentioning is Pparγ
(upregulated in parous ALDH positive MECs) is a highly
targeted gene by most microRNAs in our dataset. Pparγ
has been shown to promote the transcription of tumor-
suppressor genes like Pten [49] and Brca1 [50]. With
regards to stem cells, inhibition of Pparγ leads to the
expansion of the stem cell pool as represented by the
increased percentage of CK5+ and CD29+/CD24+ cells
[51]. Interestingly, PPARγ-deficient mice also show an
increased occurrence of hormone-dependent mammary
cancers [51]. Taken together, we speculate that increased
expression of Pparγ in parous ALDH positive MECs
contributes to the regulation of stem cell fate determin-
ation, thus controlling the incidence of tumorigenesis.
According to our in silico analysis, Pparγ is likelyregulated by microRNAs like let-7 family members,
miR-30 family members, miR-27b, miR-23ab, miR-93,
miR-25, miR-128ab, miR-320, and miR-135. In summary,
the present study elucidates the differences in the ALDH
positive MEC population in both parous and virgin glands.
It was generally observed that there are changes at both
the gene and microRNA levels in ALDH positive MECs of
both groups, and these changes could contribute to re-
duced risk of breast cancer in parous mammary glands.
Conclusion
Overall our data indicates that pregnancy alters micro-
RNAs and genes in the ALDH positive MECs. These
changes in the putative epithelial stem cell population
render it resistant to mammary carcinogenesis. Also, our
study brings forward a gene and microRNA signature
specific to the ALDH positive MECs. These can serve as
potential biomarkers and lead to the development of
novel therapeutic targets for breast cancer.
Additional file
Additional file 1: Figure S1. Proliferation assay demonstrates higher
cycling rates for virgin compared to parous ALDH positive MECs (n = 2;
each group) were subjected to analysis after EdU treatment for 2 hours.
A commercial kit was used to detect the incorporated EdU (molecular
probes, Life Technologies). A) Representative confocal images (10X) for
virgin and parous ALDH positive MECs showing the presence of cells at
S-phase (green) of the cell cycle. B) Quantitative analysis to determine
the percentage of proliferative cells in both the groups.
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